Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Stresses Cost Control Despite Strong Earnings Quarter

Oct 27 2016

• By Joseph Haas

Related Content

Bristol Still Rules Immuno-Oncology, But For How Long?

Oct 27 2016

Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last

Jul 29 2016

Bristol-Myers Boosted By Opdivo Sales, Growth Prospects

Oct 28 2015

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

Jun 28 2016

Related Companies

Bristol Myers Squibb Company

Gilead Sciences, Inc.

Additional Topics

Sales & Earnings Business Strategies Companies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window